MA33705B1 - Compositions pour l'inhalation comprenant de l'acide de montelukast et un inhibiteur de la pde-4 ou un corticosteroide inhale - Google Patents

Compositions pour l'inhalation comprenant de l'acide de montelukast et un inhibiteur de la pde-4 ou un corticosteroide inhale

Info

Publication number
MA33705B1
MA33705B1 MA32860A MA32860A MA33705B1 MA 33705 B1 MA33705 B1 MA 33705B1 MA 32860 A MA32860 A MA 32860A MA 32860 A MA32860 A MA 32860A MA 33705 B1 MA33705 B1 MA 33705B1
Authority
MA
Morocco
Prior art keywords
corticosteroid
inhibitor
pde
inhale
montelukast acid
Prior art date
Application number
MA32860A
Other languages
Arabic (ar)
English (en)
Inventor
Roch Thibert
Original Assignee
Merck Frosst Canada Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Frosst Canada Ltd filed Critical Merck Frosst Canada Ltd
Publication of MA33705B1 publication Critical patent/MA33705B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pulmonology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La présente invention concerne des compositions à inhaler renfermant de l'acide montélukast et un second agent actif choisi parmi un inhibiteur de pde4 et un corticostéroïde inhalé. L'invention a également pour objet un procédé de traitement de troubles respiratoires tels que l'asthme à l'aide de telles compositions.
MA32860A 2007-10-25 2010-05-20 Compositions pour l'inhalation comprenant de l'acide de montelukast et un inhibiteur de la pde-4 ou un corticosteroide inhale MA33705B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US32707P 2007-10-25 2007-10-25
PCT/CA2008/001874 WO2009052624A1 (fr) 2007-10-25 2008-10-23 Polythérapie

Publications (1)

Publication Number Publication Date
MA33705B1 true MA33705B1 (fr) 2012-11-01

Family

ID=40579006

Family Applications (1)

Application Number Title Priority Date Filing Date
MA32860A MA33705B1 (fr) 2007-10-25 2010-05-20 Compositions pour l'inhalation comprenant de l'acide de montelukast et un inhibiteur de la pde-4 ou un corticosteroide inhale

Country Status (19)

Country Link
US (1) US20100210611A1 (fr)
EP (1) EP2211863A4 (fr)
JP (1) JP2011500731A (fr)
KR (1) KR20100072295A (fr)
CN (1) CN101909626A (fr)
AU (1) AU2008316283A1 (fr)
CA (1) CA2701956A1 (fr)
CO (1) CO6270213A2 (fr)
CR (1) CR11439A (fr)
DO (1) DOP2010000122A (fr)
GT (1) GT201000107A (fr)
IL (1) IL205182A0 (fr)
MA (1) MA33705B1 (fr)
MX (1) MX2010004529A (fr)
NI (1) NI201000069A (fr)
NZ (1) NZ584876A (fr)
RU (1) RU2470639C2 (fr)
WO (1) WO2009052624A1 (fr)
ZA (1) ZA201002562B (fr)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012168907A1 (fr) 2011-06-10 2012-12-13 Glenmark Pharmaceuticals Sa Composition pharmaceutique comprenant du révamilast et du montélukast ou du zafirlukast
WO2014012954A1 (fr) 2012-07-18 2014-01-23 Takeda Gmbh Traitement de l'asthme sévère partiellement régulé ou non régulé
JP2017503814A (ja) 2014-01-22 2017-02-02 タケダ ゲー・エム・ベー・ハーＴａｋｅｄａ ＧｍｂＨ 部分的コントロール状態の重症喘息またはコントロール不良状態の重症喘息のｐｄｅ４インヒビターを用いた（およびロイコトリエン調節薬と組み合わせて用いた）治療
CN108267531B (zh) * 2016-12-31 2022-01-11 天津金耀集团有限公司 一种环索奈德有关物质hplc测定方法
IT201900014178A1 (it) * 2019-08-06 2021-02-06 Genetic S P A Esteri del montelukast e loro formulazioni farmaceutiche

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5837699A (en) * 1994-01-27 1998-11-17 Schering Corporation Use of mometasone furoate for treating upper airway passage diseases
US20040214805A1 (en) * 1999-11-02 2004-10-28 Smithkline Beecham Corporation Method and compositions for treating pulmonary diseases
AU2002227123A1 (en) * 2000-11-07 2002-05-21 Merck And Co., Inc. Method of treatment with a combination of a pde4 inhibitor and a leukotriene antagonist
JO2311B1 (en) * 2001-08-29 2005-09-12 ميرك فروست كندا ليمتد Alkyl inhibitors Ariel phosphodiesterase-4
IL160272A0 (en) * 2001-09-19 2004-07-25 Altana Pharma Ag Pharmaceutical compositions containing a pde4 or a pde3/4 inhibitor and a leukotriene receptor antagonist
DE10237739A1 (de) * 2002-08-17 2004-02-26 Boehringer Ingelheim Pharma Gmbh & Co. Kg Inhalative Arzneimittel enthaltend ein neues Anticholinergikum in Kombination mit Corticosteroiden und Betamimetika
US7550133B2 (en) * 2002-11-26 2009-06-23 Alexza Pharmaceuticals, Inc. Respiratory drug condensation aerosols and methods of making and using them
PL1670482T5 (pl) * 2003-09-16 2022-10-03 Covis Pharma Gmbh Zastosowanie cyklezonidu w leczeniu chorób układu oddechowego
US7553853B2 (en) * 2003-10-10 2009-06-30 Synthon Bv Solid-state montelukast
CA2550848C (fr) * 2004-02-06 2013-02-26 Meda Pharma Gmbh & Co. Kg Combinaison d'anticholinergiques et d'inhibiteurs de phosphodiesterase type 4 pour le traitement de maladies respiratoires
EP1616567A1 (fr) * 2004-07-16 2006-01-18 Boehringer Ingelheim Pharma GmbH & Co.KG Médicaments comprenant des inhibiteurs de PDE-IV et des sels de glycopyrolate pour l'inhalation
BRPI0606283A2 (pt) * 2005-03-16 2009-06-09 Elan Pharma Int Ltd formulações de antagonista de receptor de leucotrieno/corticosteróide em nanopartìcula
MX2007011273A (es) * 2005-03-16 2007-11-08 Meda Pharma Gmbh & Co Kg La combinacion de anticolinergicos y antagonistas del receptor de leucotrieno para el tratamiento de enfermedades respiratorias.
EP1931338A4 (fr) * 2005-09-28 2009-05-27 Merck Frosst Canada Inc Formulation de poudre aerosol comprenant un lactose tamise

Also Published As

Publication number Publication date
CA2701956A1 (fr) 2009-04-30
CN101909626A (zh) 2010-12-08
ZA201002562B (en) 2011-06-29
EP2211863A4 (fr) 2012-07-25
WO2009052624A9 (fr) 2010-11-25
CO6270213A2 (es) 2011-04-20
JP2011500731A (ja) 2011-01-06
KR20100072295A (ko) 2010-06-30
RU2470639C2 (ru) 2012-12-27
GT201000107A (es) 2012-03-13
NI201000069A (es) 2010-08-23
MX2010004529A (es) 2010-05-10
AU2008316283A1 (en) 2009-04-30
WO2009052624A1 (fr) 2009-04-30
US20100210611A1 (en) 2010-08-19
IL205182A0 (en) 2010-11-30
NZ584876A (en) 2012-06-29
EP2211863A1 (fr) 2010-08-04
DOP2010000122A (es) 2010-07-15
CR11439A (es) 2010-06-21
RU2010120806A (ru) 2011-11-27

Similar Documents

Publication Publication Date Title
MA34449B1 (fr) Formulation de poudre seche comprenant un inhibiteur de phosphodiesterase
MA33705B1 (fr) Compositions pour l'inhalation comprenant de l'acide de montelukast et un inhibiteur de la pde-4 ou un corticosteroide inhale
MA31845B1 (fr) Pipéridino-dihydrothiénopyrimidines substituées
AU2008317965B2 (en) Osmolyte-containing preparation for use in case of dry mucous membranes
Davenport et al. Systemic and behavioral effects of intranasal administration of silver nanoparticles
MX2008010222A (es) Antibioticos nebulizados para terapia de inhalacion.
MA33299B1 (fr) Nouvelle formulation de naproxène
MX2012012225A (es) Profármacos de agentes tearapéuticos de liberación de óxido nítrico.
DE60231826D1 (de) Abgabevorrichtung für arzneimittel
JP2008533072A5 (fr)
BRPI0609784B8 (pt) compostos éster de n-alquilcarbonil-aminoácido e n-alquilcarbonil-amino lactona, composição, e, uso de um composto
TNSN07063A1 (fr) Utilisations therapeutiques d'inhibiteurs de rtp801
MA32035B1 (fr) Composes tricycliques servant de modulateurs de synthese de tnf-alpha et d'inhibiteurs de pde4
MX2010001236A (es) Derivados de 5-fenil-isoxazol-3-carboxamida como moduladores del receptor de potencial transitorio v1 (trpv1).
JP6234899B2 (ja) 喘息及びアレルギー性鼻炎の治療におけるアルギナーゼ阻害剤の使用
MA32798B1 (fr) Acides naphtylacétiques
NO20054180L (no) Behandling av bakterielle sykdommer i andedrettsorganene ved lokal tilforsel av fluorkinoloner
MA38349A1 (fr) Œstra-1,3,5(10),16-tétraéno-3-carboxamide pour inhiber la 17-bêta-hydroxystéroïde déshydrogénase (akr1c3)
JP2006316063A (ja) ペトロラタムを基にした鼻用軟膏
MXPA03011702A (es) Composicion que comprende un inhibidor de fosodiesterasa 4 y un antagonista de receptor h1 y el uso de los mismos para la elaboracion de un medicamento para el tratamiento de enfermedades respiratorias.
JP2011500731A5 (fr)
MA30567B1 (fr) Dérivés d'acide phénylacétique.
EP2826479B1 (fr) Agent pour faire régresser les maladies pulmonaires obstructives chroniques
EA201100422A1 (ru) (фенил)амиды 7-(пиперазин-1-илметил)-1h-индол-2-карбоновой кислоты и родственные соединения в качестве ингибиторов мар-киназы p38 для лечения заболеваний дыхательных путей
ATE475409T1 (de) Mikroemulsionsformulierungen mit bestimmten substanz p antagonisten